Hui–Hsuan Kuo

This paper uses patient-derived hiPSC-CMs to identify cyproheptadine as a therapeutic for LMNA-related DCM by revealing shared and variant-specific disease mechanisms.

This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

The paper analyzes whole-genome sequencing data from a pan-cancer cohort to define HRD, showing it extends beyond BRCA1/2 mutations and highlights the benefits of WGS over commercial assays for HRD detection.

The paper develops co-culture strategies of tumor organoids with autologous T-cells to screen immune-checkpoint and targeted therapy combinations.